Please assess the completion status of the following clinical trial:

Trial Title: A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with migraine with or without aura fulfilling the International Classification of Headache Disorders (ICHD)-2.~* History of disabling migraine for at least 1 year.~* Migraine Disability Assessment Test (MIDAS) score ≥11.~* Migraine onset before the age of 50 years.~* History of 3-8 migraine attacks per month and \<15 headache days per month during the past 3 months.~Exclusion Criteria:~* Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets.~* History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the patient at increased risk of seizures.~* History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.~* History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy).~* History of orthostatic hypotension with syncope.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50 milligram (mg) Lasmiditan (Type: EXPERIMENTAL): 50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
- 100 mg Lasmiditan (Type: EXPERIMENTAL): 100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
- 200 mg Lasmiditan (Type: EXPERIMENTAL): 200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.

Based on this trial design, predict the completion outcome and termination type (if applicable).